Thermo Fisher Scientific Inc (NYSE:TMO)‘s stock had its “overweight” rating restated by analysts at Barclays PLC in a report released on Monday, Marketbeat.com reports. They currently have a $215.00 price objective on the medical research company’s stock, up from their prior price objective of $200.00. Barclays PLC’s price objective would indicate a potential upside of 14.18% from the stock’s previous close.

Several other equities analysts also recently commented on TMO. Deutsche Bank AG set a $200.00 price target on Thermo Fisher Scientific and gave the company a “buy” rating in a report on Saturday, June 10th. Zacks Investment Research downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, September 18th. Bank of America Corporation reiterated a “buy” rating and set a $210.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. Cleveland Research upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a report on Thursday, July 20th. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $200.00 price target (up previously from $195.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 13th. One equities research analyst has rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. Thermo Fisher Scientific presently has an average rating of “Buy” and an average price target of $195.33.

Thermo Fisher Scientific (NYSE TMO) traded down 0.52% during midday trading on Monday, reaching $187.33. 1,582,063 shares of the company’s stock traded hands. The stock has a market capitalization of $73.08 billion, a price-to-earnings ratio of 32.64 and a beta of 1.05. The company’s 50-day moving average price is $181.07 and its 200 day moving average price is $171.15. Thermo Fisher Scientific has a 52 week low of $139.07 and a 52 week high of $194.30.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, topping analysts’ consensus estimates of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The firm had revenue of $5 billion for the quarter, compared to the consensus estimate of $4.92 billion. During the same quarter in the prior year, the company posted $2.03 earnings per share. The firm’s revenue was up 10.2% on a year-over-year basis. On average, equities research analysts expect that Thermo Fisher Scientific will post $9.35 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was first posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/09/25/thermo-fisher-scientific-inc-tmo-receives-overweight-rating-from-barclays-plc.html.

In other news, Director C Martin Harris sold 360 shares of the firm’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total value of $65,149.20. Following the sale, the director now owns 5,312 shares in the company, valued at $961,312.64. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Daniel P. Shine sold 2,026 shares of the firm’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $180.97, for a total transaction of $366,645.22. Following the completion of the sale, the insider now owns 20,682 shares in the company, valued at approximately $3,742,821.54. The disclosure for this sale can be found here. In the last 90 days, insiders sold 52,738 shares of company stock worth $9,302,112. 0.49% of the stock is currently owned by corporate insiders.

Several institutional investors have recently made changes to their positions in TMO. Proficio Capital Partners LLC grew its stake in shares of Thermo Fisher Scientific by 71.5% in the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock worth $105,000 after acquiring an additional 253 shares during the last quarter. Chicago Partners Investment Group LLC bought a new position in Thermo Fisher Scientific in the second quarter worth $108,000. Cribstone Capital Management LLC lifted its position in Thermo Fisher Scientific by 8.7% in the second quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock worth $109,000 after purchasing an additional 50 shares during the period. Sharkey Howes & Javer lifted its position in Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after purchasing an additional 7 shares during the period. Finally, Shine Investment Advisory Services Inc. bought a new position in Thermo Fisher Scientific in the second quarter worth $113,000. Institutional investors and hedge funds own 83.36% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.